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INTRODUCTION: Detection of Epidermal Growth Factor Receptor (EGFR) mutational status is required to determine optimal treatment of non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: In this retrospective cohort, we evaluated EGFR mutational status including the resistance mutation T790M using SNapShot technology in Cerebro-spinal fluid (CSF) in NSCLC patients presenting with leptomeningeal metastasis (LM) between 2012 and 2016. RESULTS: Among 16 patients with LM, 13 had an EGFR mutation (exon 19, n=7; exon 21, n=6), 1 had a KRAS mutation, 1 had an ALK rearrangement, and 1 a HER2 mutation at NSCLC diagnosis. LM were diagnosed after a median of 19 months (range, 0-115) after lung cancer diagnosis. CSF molecular analyses were performed at LM diagnosis (n=12) or for the evaluation of mutations during the management of a known LM (n=4). At the time of molecular CSF analysis, malignant cells were observed in the CSF of 15 patients. The known molecular alteration was found in CSF in all 13 initially EGFR mutated patients. A supplementary EGFR T790M mutation was detected in the CSF of one patient. In another patient, the EGFR mutation was detected whereas no malignant cells were observed using standard cytology. Initial treatments for EGFRmutated LM included first-or second-generation tyrosine kinase inhibitors (TKI, n=9) systemic chemotherapy (n=5), immunotherapy (n=1) and intraCSF liposomal cytarabine combined with systemic treatment (n=8) or alone (n=1). Median overall was 4.7 months (range, 0.5-20) in the whole population whereas 5.7 months (range, 0.5-20) in the EGFR mutated population. CONCLUSION: CSF molecular analysis may identify EGFR mutations, including the T790M resistance mutation, even in the absence of malignant cells in the CSF with standard cytology. Specific therapeutic strategies may benefit to EGFR-mutated NSCLC patients with LM. Given their limited survival in conjunction with significant symptom burden and cognitive impairment, patients with BM are likely to benefit from hospice enrollment. This study evaluates regional hospice enrollment patterns in elderly patients with BM. METHODS: Administrative claims were obtained for deceased Medicare beneficiaries with BM (ICD-9 code 198.3) from 2012-2015 within the UAB Health System Cancer Community Network including AL, FL, GA, MS, and TN. Hospice enrollment patterns were recorded as early (>2 weeks prior to death), late (3-14 days prior to death) or very late (≤2 days prior to death). Logistic regression analysis was performed to determine if demographic factors were associated with hospice enrollment patterns. RESULTS: Among 948 patients with BM who died during the claims period, there were 378 (40%) early, 251 (27%) late, and 99 (10%) very late hospice enrollments. Another 220 patients (23%) were never enrolled prior to death. Mean age was 74 years. Median time from hospice enrollment to death was 16 days. In multivariable analysis controlling for other demographic factors, non-white patients were less likely than their white counterparts to receive any hospice referral (OR 0.43, 95% CI 0.22-0.85, p=0.016), and females were less likely than males to receive a very late referral (OR 0.37, 95% 0.14-0.98, p=0.045). Very late or no enrollment occurred in 34% of BM patients versus 24% (n=383) of patients with primary malignant brain tumors within the same claims period (p=0.001). CONCLUSION: Late hospice enrollment (within the last two weeks of life) in Medicare patients with BM is common (60%). BM patients of male gender and/or non-white race are significantly less likely to have timely hospice enrollments, as are patients with BM versus primary brain tumors. . Currently, the most common indication for Ommaya reservoir insertion in adults is for patients with hematologic or leptomeningeal disorders. We wished to examine short-and-long-term outcomes in patients treated with Ommaya reservoirs at our institution. METH-ODS: We retrospectively evaluated all operative cases of Ommaya reservoir insertion from 2000-2014 by the senior author (JFM). Patient demographic data, surgical outcomes, peri-operative complications, and long-term outcomes were collected. RESULTS: 28 patients underwent image-guided Ommaya reservoir insertion by the senior author (JFM) over the study period (43.3 +/-17.3 years; 35.7% female). The most common indications for placement were acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and leptomeningeal carcinomatosis. There were two complications: one asymptomatic peri-operative intracranial hemorrhage (3.6%), and one early infection (3.6%) requiring catheter removal and intravenous antibiotics. All catheters were accurately placed (100% success rate). Data collection for long-term outcome is currently underway. CONCLUSIONS: Our findings suggest minimal short-term morbidity with improved accuracy and decreased complications using an image-guided approach compared with a traditional approach. There were no peri-operative deaths in our series. Our results support routine use of intra-operative image guidance for proximal catheter insertion in elective Ommaya reservoir placement for intraventricular chemotherapy.
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